Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17157509rdf:typepubmed:Citationlld:pubmed
pubmed-article:17157509lifeskim:mentionsumls-concept:C0080093lld:lifeskim
pubmed-article:17157509lifeskim:mentionsumls-concept:C0038477lld:lifeskim
pubmed-article:17157509pubmed:issue3lld:pubmed
pubmed-article:17157509pubmed:dateCreated2007-1-8lld:pubmed
pubmed-article:17157509pubmed:abstractTextPrompted by our interest in neuroprotective agents with multiple mechanisms of action, we assessed the structure-activity relationship of a series of pentacycloundecylamine derivatives previously shown to have both L-type calcium channel blocking activity and N-methyl-d-aspartate receptor (NMDAR) antagonistic activity. We utilized a functional assay to measure NMDAR channel block using (45)Ca(2+) influx into synaptoneurosomes. The cage amine 8-benzylamino-8,11-oxapentacyclo[5.4.0.0(2,6). 0(3,10).0(5,9)]undecane (NPG1-01) proved to be the most potent experimental compound with an IC(50) of 2.98microM, while 8-amino-pentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecane had the next most potent IC(50) of 4.06microM. Increasing the polycyclic cage size of NGP1-01 from a pentacycloundecane to a tridecane cage structure, but retaining the N-benzyl moiety decreased potency 10-fold, indicating a limitation on the volume of the cage that can be accommodated in the channel binding site. In the presence of NGP1-01, NMDA/glycine-induced maximal (45)Ca(2+) influx was attenuated by 34% with an insignificant effect on agonist potency. These results are consistent with uncompetitive antagonism for this group of compounds. Radioligand binding studies with [(3)H]MK-801 or [(3)H]TCP showed little or no displacement of these ligands by pentacycloundecylamines, suggesting that the latter compounds bind to a unique site in the NMDAR channel. The pentacycloundecylamines tested represent a novel group of NMDAR antagonists that have potential as therapeutic agents for neurodegenerative diseases including Parkinson's and Alzheimer's disease.lld:pubmed
pubmed-article:17157509pubmed:languageenglld:pubmed
pubmed-article:17157509pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17157509pubmed:citationSubsetIMlld:pubmed
pubmed-article:17157509pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17157509pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17157509pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17157509pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17157509pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17157509pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17157509pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17157509pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17157509pubmed:statusMEDLINElld:pubmed
pubmed-article:17157509pubmed:monthFeblld:pubmed
pubmed-article:17157509pubmed:issn0968-0896lld:pubmed
pubmed-article:17157509pubmed:authorpubmed-author:BloomquistJef...lld:pubmed
pubmed-article:17157509pubmed:authorpubmed-author:MalanSarel...lld:pubmed
pubmed-article:17157509pubmed:authorpubmed-author:Van der...lld:pubmed
pubmed-article:17157509pubmed:authorpubmed-author:GeldenhuysWer...lld:pubmed
pubmed-article:17157509pubmed:issnTypePrintlld:pubmed
pubmed-article:17157509pubmed:day1lld:pubmed
pubmed-article:17157509pubmed:volume15lld:pubmed
pubmed-article:17157509pubmed:ownerNLMlld:pubmed
pubmed-article:17157509pubmed:authorsCompleteYlld:pubmed
pubmed-article:17157509pubmed:pagination1525-32lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:meshHeadingpubmed-meshheading:17157509...lld:pubmed
pubmed-article:17157509pubmed:year2007lld:pubmed
pubmed-article:17157509pubmed:articleTitleStructure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor.lld:pubmed
pubmed-article:17157509pubmed:affiliationDepartment of Pharmaceutical Sciences, Northeastern Ohio Universities College of Pharmacy, Rootstown, OH 44272-0095, USA.lld:pubmed
pubmed-article:17157509pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17157509pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:17157509lld:chembl